Screener / SEC EDGAR /CIK 0001551306 /10-K filed Feb 27, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Health Services

Progyny, Inc. PGNY

Compare with peers Embed
Earnings releases

Latest results release: Nov 4, 2026

8-K item 2.02, exhibit 99

What PGNY's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

What the company says its adjusted numbers leave out:

We calculate Adjusted Earnings per Diluted Share as net income per diluted share excluding the impact of stock-based compensation, adjusted for the impact of taxes. release Nov 4, 2026

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 4, 2026 · EX-99.1

Progyny, Inc. Announces Third Quarter 2026 Results

Open on SEC

Reports Record Third Quarter Results for Revenue, Gross Profit, Adjusted EBITDA and Net Income

Selling Season Yields Record 1.3 Million New Covered Lives with Another Year of Near 100% Retention

- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended September 30, 2026 (“the third quarter of 2026”), as compared to the three-month period ended September 30, 2025 (“the third quarter of 2025” or “the prior year period”).

“We're exceptionally pleased with the results of our most recent selling season, where our momentum extended even into its latest stages, yielding 1.3 million new covered lives, our most ever in a single season, and over 85 new clients,” said Pete Anevski, Chief Executive Officer of Progyny. “Beyond new sales activity, our season also focuses on renewing the existing base, where we once again achieved a near 100% retention for 2027 as well as strong demand from those accounts to expand their relationships with us through more comprehensive coverage and the further adoption of our newest services in pregnancy, parenting and menopause support.

“More than ever, these results once again affirm the critical importance of these benefits to employers,” continued Anevski. “We believe the energy and success we're seeing reflect how Progyny remains uniquely positioned to consistently deliver meaningful value and cost trend control to employers, which is particularly impactful given the pressures employers are facing from broader medical cost inflation.

“As we look into next year, we believe we're well-positioned to extend this momentum into 2027, as we're exiting the year with our strongest ever set-up in terms of our number of opportunities and the overall size and quality of the pipeline, as our demonstrated ability to effectively bend the cost curve positions us well for continued success.”

“We achieved strong top- and bottom-line growth this quarter, reflecting that member engagement was consistent with our expectations, and we are pleased to be in a position to raise the midpoint of our full year guidance,” said Mark Livingston, Chief Financial Officer of Progyny. “In addition to the strong results this quarter, we continued to maintain a high conversion of Adjusted EBITDA to operating cash flow, which has provided us with the flexibility to continue investing in our platform while also returning value to shareholders through the repurchase of nearly 11 million shares this year.” Third Quarter 2026 Highlights:

(unaudited; in thousands, except per 3Q 2026 3Q 2025 share amounts) Revenue $341,254 $313,346 Gross Profit $83,740 $72,835 Gross Margin 24.5% 23.2% Net Income $26,252 $13,864 Net Income per Diluted Share1 $0.32 $0.15 Adjusted Earnings per Diluted $0.52 $0.45 Share2 Adjusted EBITDA2 $58,439 $54,968 Adjusted EBITDA Margin2 17.1% 17.5% Trailing Twelve-Month Operating Cash $207,182 $208,153 Flow

1. Net income per diluted share reflects weighted-average shares outstanding as adjusted for potential dilutive securities, including options, restricted stock units, and shares issuable under the employee stock purchase plan . 1 2. Adjusted Earnings per Diluted Share, Adjusted EBITDA, and Adjusted EBITDA margin are financial measures that are not required by, or presented in accordance with U.S. generally accepted accounting principles ("GAAP"). Please see Annex A of this press release for a reconciliation of Adjusted Earnings per Diluted Share to earnings per share, and Adjusted EBITDA to net income, the most directly comparable financial measures stated in accordance with GAAP for each of the periods presented. We calculate Adjusted Earnings per Diluted Share as net income per diluted share excluding the impact of stock-based compensation, adjusted for the impact of taxes. We calculate Adjusted EBITDA margin as Adjusted EBITDA divided by revenue.

Revenue was $341.3 million, an 8.9% increase as compared to the $313.3 million reported in the third quarter of 2025, due to an increase in the number of clients and covered lives.

• Fertility benefit services revenue was $223.4 million, a 10.6% increase from the $201.9 million reported in the third quarter of 2025.

• Pharmacy benefit services revenue was $117.9 million, a 5.8% increase as compared to the $111.4 million reported in the third quarter of 2025.

Gross profit was $83.7 million, an increase of 15% from the $72.8 million reported in the third quarter of 2025, reflecting ongoing efficiencies realized in the delivery of our care management services as well as a decrease in stock- based compensation expense . Gross margin was 24.5%, as compared to 23.2% reported in the prior year .

Net income was $26.3 million, or $0.32 income per diluted share, as compared to the $13.9 million, or $0.15 income per diluted share, reported in the third quarter of 2025. The higher net income was due primarily to the higher gross profit and lower stock-based compensation expense, which was partially offset by lower interest and other income, net.

Adjusted EBITDA was $58.4 million, an increase of 6.3% as compared to the $55.0 million reported in the third quarter of 2025, as the higher gross profit was partially offset by planned investments to expand the features and functionality of our platform . Adjusted EBITDA margin was 17.1% as compared to the 17.5% Adjusted EBITDA margin in the third quarter of 2025. Refer to Annex A for a reconciliation of Adjusted EBITDA to net income.

Net cash provided by operating activities in the third quarter of 2026 was $56.6 million, as compared to $50.7 million in the prior year period. Cash flow reflects the timing impact of certain working capital items in both periods.

As of September 30, 2026, the Company had total working capital of approximately $224.4 million and no debt. This included cash and cash equivalents and marketable securities of $195.6 million, a decrease of $41.3 million from the balances as of June 30, 2026, as the operating cash flow generated was offset by share repurchase activity during the quarter. The Company's $200 million revolving credit facility remains undrawn, and the Company has no planned use for the facility at this time.

During the third quarter of 2026, the Company repurchased nearly 3 million shares of its common stock for a total cost of $82.7 million through its May 2026 share repurchase program, which provided for a total authorization of up to $200 million. To date, the Company has repurchased nearly 5.5 million shares of its common stock under this most recent program, and approximately $51 million remains under the existing authorization. In combination with its predecessor program which began in November 2025 and concluded earlier this year, the Company has now repurchased nearly 11 million shares thus far in 2026, and approximately 14.3 million shares overall since November 2025.

The Company had 607 fertility and family building clients as of September 30, 2026, as compared to 553 clients as of September 30, 2025. 2

* Represents the number of ART cycles performed, including IVF with a fresh embryo transfer, IVF freeze all cycles/embryo banking, frozen embryo transfers, and egg freezing. Includes ART cycles performed in the first half of 2025 under the extended transition of care agreement with the large client who did not renew its service agreement.

** Represents the member utilization rate for all fertility and family building services, including, but not limited to, ART cycles, initial consultations, IUIs, and genetic testing. The utilization rate for all members includes all unique members (female and male) who utilize the benefit during that period, while the utilization rate for female only includes only unique females who utilize the benefit during that period. For purposes of calculating utilization rates in any given period, the results reflect the number of unique members utilizing the benefit for that period. Individual periods cannot be combined as member treatments may span multiple periods. Utilization for the nine month period in 2025 excludes activity under the extended transition of care agreement that ended June 30, 2025 with the large client who did not renew its service agreement, as only members meeting certain criteria were eligible to use the benefit.

***Includes approximately 300,000 members from a single client who are not reflected in utilization as a result of the client's chosen benefit design. 2025 excludes the limited number of members who were eligible to use the benefit under the extended transition of care agreement that ended June 30, 2025 with the large client who did not renew its service agreement.

As the fourth quarter begins, member activity continues to remain healthy. In light of the strong results over the first nine months of the year, as well as our expectations for member engagement over the remainder of the year, we're raising the midpoint of our full year guidance.

The majority of the clients and lives added in the most recent selling season are expected to go live in the first quarter of 2027, though a meaningful number of lives are expected to launch mid-year. In addition, a number of the newest clients have already launched their benefit in 2026. Once all new clients are live in 2027, the Company anticipates having in excess of 660 clients, representing approximately 8.3 million covered lives.

As it relates to 2027, consistent with past practice, the Company anticipates providing financial guidance when it reports its year-end results in February. The Company is providing the following financial guidance for both the three- month and full year periods ending December 31, 2026.

o Revenue is projected to be $1.365 billion to $1.385 billion, reflecting growth of 5.9% to 7.5%; excluding the $48.5 million of revenue in 2025 from the large client who was under a transition agreement in the first half of 2025, revenue is expected to increase by 10.1% to 11.7% o Net income is projected to be $107.0 million to $110.6 million, or $1.30 to $1.35 per diluted share, on the basis of approximately 82.0 million assumed weighted-average fully diluted-shares outstanding o Adjusted EBITDA 1 is projected to be $235.0 million to $240.0 million

o Revenue is projected to be $344.7 million to $364.7 million, reflecting growth of 8.3% to 14.6% o Net income is projected to be $28.5 million to $32.1 million, or $0.36 to $0.41 per diluted share, on the basis of approximately 79.0 million assumed weighted-average fully diluted-shares outstanding o Adjusted EBITDA 1 is projected to be $57.9 million to $62.9 million

1. Adjusted EBITDA and Adjusted earnings per diluted share are financial measures that are not required by, or presented in accordance with, GAAP. Please see Annex A of this press release for a reconciliation of forward-looking Adjusted EBITDA to forward-looking net 3 income and Adjusted net income to net income, the most directly comparable financial measures stated in accordance with GAAP, for the period presented.

Progyny will host a conference call at 4:45 P.M. Eastern Time (1:45 p.m. Pacific Time) today, November 4, 2026, to discuss its financial results. Interested participants from the United States may join by calling 1.866.825.7331 and using conference ID 265484. Participants from international locations may join by calling 1.973.413.6106 and using the same conference ID. A replay of the call will be available until November 11, 2026 at 5:00 p.m. Eastern Time by dialing 1.800.332.6854 (U.S. participants) or 1.973.528.0005 (international) and entering passcode 265484. A live audio webcast of the call and subsequent replay will also be available through the Events & Presentations section of the Company’s Investor Relations website at investors.progyny.com.

Progyny (Nasdaq: PGNY) is a global leader in women’s health and family building solutions, trusted by leading employers, health plans, and benefit purchasers worldwide. Through its comprehensive and personalized approach, Progyny supports members across fertility and family building, pregnancy and postpartum, menopause and midlife, and parent and child well-being journeys. Progyny combines differentiated clinical care, integrated pharmacy support through Progyny Rx®, and personalized guidance from Progyny Care Advocates® to deliver improved member experiences and better health outcomes. For more information, visit www.progyny.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact, are forward-looking statements including, without limitation, statements regarding our financial outlook for the fourth quarter and full year 2026, including the impact of our sales season and client launches; our anticipated number of clients and covered lives for 2026; our expected utilization rates and mix; the demand for our solutions; our expectations for our selling season for 2027 launches; our positioning to successfully manage economic uncertainty on our business; the timing of client decisions; our ability to retain existing clients and acquire new clients; and our business strategy, plans, goals and expectations concerning our market position, future operations, and other financial and operating information. The words “anticipates,” “assumes,” “believe,” “contemplate,” “continues, ” “could,” “estimates,” “expects,” “future,” “intends,” “may,” “plans,” “predict,” “potential,” “project,” “seeks,” “should,” “target,” “will,” and the negative of these or similar expressions and phrases are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions.

Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, without limitation, failure to meet our publicly announced guidance or other expectations about our business; competition in the market in which we operate; our history of operating losses and ability to sustain profitability; unfavorable conditions in our industry or the United States economy; our limited operating history and the difficulty in predicting our future results of operations; our ability to attract and retain clients and increase the adoption of services within our client base; the loss of any of our largest client accounts; changes in the technology industry; changes or developments in the health insurance market; negative publicity in the health benefits industry; lags, failures or security breaches in our computer systems or those of our vendors; a significant change in the utilization of our solutions; our ability to offer high-quality support; positive references from our existing clients; our ability to develop and expand our marketing and sales capabilities; the rate of growth of our future revenue; the accuracy of the estimates and assumptions we use to determine the size of target markets; our ability to successfully manage our growth; reductions in employee benefits spending; seasonal fluctuations in our sales; the adoption of new solutions and services by our clients or members; our ability to innovate and develop new offerings; our ability to adapt and respond to the changing medical landscape, 4 regulations, and client needs, requirements or preferences; our ability to maintain and enhance our brand; our ability to attract and retain members of our management team, key employees, or other qualified personnel; risks related to any litigation against us; our ability to maintain our Center of Excellence network of healthcare providers; our strategic relationships with and monitoring of third parties; our ability to maintain our pharmacy distribution network if there is a disruption to our network or its associated supply chains; our relationship with key pharmacy program partners or any decline in rebates provided by them; our ability to maintain our relationships with benefits consultants; exposure to credit risk from our members; risks related to government regulation; risks related to our business with government entities; our ability to protect our intellectual property rights; risks related to acquisitions, strategic investments, or partnerships; federal tax reform and changes to our effective tax rate; the imposition of state and local state taxes; our ability to utilize a portion of our net operating loss or research tax credit carryforwards; our ability to develop or maintain effective internal control over financial reporting; and our ability to adapt and respond to the changing SEC or stakeholder expectations regarding environmental, social and governance practices. For a detailed discussion of these and other risk factors, please refer to our filings with the Securities and Exchange Commission (the “SEC”), including in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and subsequent reports that we file with the SEC, which are available at http://investors.progyny.com and on the SEC’s website at https://www.sec.gov .

Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this press release. Our actual future results could differ materially from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons.

In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), this press release and the accompanying tables include the non-GAAP financial measures Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share.

Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share are supplemental financial measures that are not required by, or presented in accordance with, GAAP. We believe that these non-GAAP measures, when taken together with our GAAP financial results, provide meaningful supplemental information regarding our operating performance and facilitates internal comparisons of our historical operating performance on a more consistent basis by excluding certain items that may not be indicative of our business, results of operations or outlook. In particular, we believe that the use of Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share are helpful to our investors as they are measures used by management in assessing the health of our business, determining incentive compensation, evaluating our operating performance, and for internal planning and forecasting purposes.

Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share are presented for supplemental informational purposes only, have limitations as analytical tools and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Some of the limitations of Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share include: (1) it does not properly reflect capital commitments to be paid in the future; (2) although depreciation and amortization are non- cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures; (3) it does not consider the impact of stock-based compensation expense; (4) it does not reflect other non-operating income and expenses, including interest and other income, net; and (5) it does not reflect tax payments that may represent a reduction in cash available to us. In addition, our non-GAAP measures may not be comparable to similarly titled measures of other companies because they may not calculate such measures in the same manner as we calculate these measures, limiting their usefulness as comparative measures. Because of these limitations, when evaluating our performance, you should consider Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share alongside other financial performance measures, including our net income, gross margin, and our other GAAP results. 5 We calculate Adjusted EBITDA as net income, adjusted to exclude depreciation and amortization; stock-based compensation expense; interest and other income, net; and provision for income taxes. We calculate Adjusted EBITDA margin as Adjusted EBITDA divided by revenue. We calculate Adjusted earnings per diluted share as net income per diluted share excluding the impact of stock-based compensation, adjusted for the associated impact of taxes. Please see Annex A: “Reconciliation of GAAP to Non-GAAP Financial Measures” elsewhere in this press release. For Further Information, Please Contact:

ASSETS September 30, December 31, Current assets: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash $ 116,820 $ 112,238 equivalents Marketable securities 78,765 197,858 Accounts receivable, net of $54,156 and $55,659 of allowances 249,182 220,287 at September 30, 2026 and December 31, 2025, respectively Prepaid expenses and other current 19,634 21,392 assets Total current assets 464,401 551,775 Property and equipment, 50,252 29,927 net Operating lease 22,872 24,990 right-of-use assets Goodwill 19,832 19,978 Intangible assets, net 5,527 6,216 Deferred tax assets, 93,083 93,013 net Other noncurrent assets 19,826 16,536 Total assets $ 675,793 $ 742,435 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 148,001 $ 124,071 Accrued expenses and other current 92,038 78,320 liabilities Total current 240,039 202,391 liabilities Operating lease 21,726 24,000 noncurrent liabilities Total liabilities 261,765 226,391 Commitments and Contingencies STOCKHOLDERS' EQUITY Common stock, $0.0001 par value; 1,000,000,000 shares authorized; at September 30, 2026 and December 31, 2025, respectively; 9 9 100,087,996 and 99,049,485 shares issued; 74,723,072 and 83,365,696 outstanding at September 30, 2026 and December 31, 2025, respectively Additional paid-in 753,524 700,785 capital Treasury stock, at cost, $0.0001 par value; 25,980,904 and 16,299,769 shares -621,041 -388,075 at September 30, 2026 and December 31, 2025, respectively Accumulated earnings 281,363 202,827 Accumulated other 173 498 comprehensive income Total stockholders’ 414,028 516,044 equity Total liabilities and stockholders’ $ 675,793 $ 742,435 equity

Nine Months Ended September 30, OPERATING ACTIVITIES 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 78,536 $ 46,035 Adjustments to reconcile net income to net cash provided by operating activities: Deferred tax expense 29 31 Non-cash interest expense 591 279 Depreciation and 5,257 3,581 amortization Loss on disposal of property and 711 79 equipment Stock-based compensation 61,305 97,068 expense Bad debt expense 13,243 15,345 Net accretion of discounts on marketable 1,345 -432 securities Changes in operating assets and liabilities: Accounts receivable, net -42,161 -32,155 Prepaid expenses and other current 2,811 -14,859 assets Accounts payable 23,799 27,660 Accrued expenses and other current 11,900 13,317 liabilities Other noncurrent assets and -4,387 40 liabilities Net cash provided by operating 152,979 155,989 activities INVESTING ACTIVITIES Purchase of property and -21,931 -12,796 equipment, net Purchase of marketable -34,162 -311,513 securities Sale of marketable 151,222 166,380 securities Acquisition of business, net of cash — -9,340 acquired Net cash provided by (used in) investing 95,129 -167,269 activities FINANCING ACTIVITIES Repurchase of common stock -231,406 — Payment of excise tax from repurchase of -528 — common stock Proceeds from exercise of 38 23 stock options Issuance costs on credit — -3,087 facility Payment of employee taxes related to -12,563 -8,820 equity awards Proceeds from contributions to employee 1,051 781 stock purchase plan Net cash used in financing -243,408 -11,103 activities Effect of exchange rate changes on cash, -93 49 cash equivalents, and restricted cash Net increase (decrease) in cash, cash 4,607 -22,334 equivalents, and restricted cash Cash, cash equivalents, and restricted 114,193 162,314 cash, beginning of period Cash, cash equivalents, and restricted $ 118,800 $ 139,980 cash, end of period Cash and cash equivalents $ 116,820 $ 133,982 Restricted cash included within prepaid 1,054 — expenses and other current assets Restricted cash included within other 926 5,998 noncurrent assets Total cash, cash equivalents, and $ 118,800 $ 139,980 restricted cash SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash paid for income taxes, net of $ 32,643 $ 39,898 refunds received SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES Additions of property and equipment, net included in accounts $ 2,399 $ 781 payable and accrued expenses Repurchases of common stock recorded in accrued expenses and other $ 1,501 $ — current liabilities Excise tax payable on common stock included in accrued $ 2,061 $ — expenses and other current liabilities Payment of employee taxes related to equity awards included in $ 291 $ 22 accrued expenses and other current liabilities

(in thousands, except share and per share amounts) Costs of Services, Gross Margin and Operating Expenses Excluding Stock-Based Compensation Calculation

The following table provides a reconciliation of cost of services, gross profit, sales and marketing and general and administrative expenses to each of these measures excluding the impact of stock-based compensation expense for each of the periods presented:

The following table provides a reconciliation of net income to Adjusted Earnings Per Diluted Share for each of the periods presented:

The following table provides a reconciliation of net income to Adjusted EBITDA for each of the periods presented:

11 Reconciliation of Non-GAAP Financial Guidance for the Three Months Ending December 31, 2026 and Year Ending December 31, 2026

* All of the numbers in the tables above reflect our future outlook as of the date hereof. Net income, Adjusted Net Income and Adjusted EBITDA ranges do not reflect any estimate for other potential activities and transactions, nor do they contemplate any discrete income tax items, including the income tax impact related to equity compensation activity. 12 Assisted Reproductive Technology (ART) Cycles per Unique Female Utilizer

The following tables provide historical trend and guidance assumptions for average members, female utilization rate, and ART Cycles per Unique Female Utilizer for the full year and quarterly periods presented:

1 Calculations for 2024, 2025, and 2026 exclude approximately 300,000 members from a single client not reflected in female utilizers as a result of the client's chosen benefit design.

2 Calculations exclude activity from a large client whose program discontinued for 2025, but who allowed for an extended period of transition of care for certain members during the first half of 2025.

*Calculations for 2024, 2025, and 2026 exclude approximately 300,000 members from a single client not reflected in female utilizers as a result of the client's chosen benefit design.

Full text with the tables
                                                                                
               Progyny, Inc. Announces Third Quarter 2026 Results               
                                                                                
Reports Record Third Quarter Results for Revenue, Gross Profit, Adjusted EBITDA 
                                 and Net Income                                 
                                                                                
Selling Season Yields Record 1.3 Million New Covered Lives with Another Year of 
                              Near 100% Retention                               
                                                                                
                  Raises Midpoint of Full Year Guidance Ranges                  
                                                                                
  NEW YORK, November 4, 2026 /GlobeNewswire/                                    
                                                                                
- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in
women's health and family building solutions, today announced its financial
results for the three-month period ended September 30, 2026 (“the third quarter
of 2026”), as compared to the three-month period ended September 30, 2025 (“the
third quarter of 2025” or “the prior year period”).

“We're exceptionally pleased with the results of our most recent selling season,
where our momentum extended even into its latest stages, yielding 1.3 million
new covered lives, our most ever in a single season, and over 85 new clients,”
said Pete Anevski, Chief Executive Officer of Progyny. “Beyond new sales
activity, our season also focuses on renewing the existing base, where we once
again achieved a near 100% retention for 2027 as well as strong demand from
those accounts to expand their relationships with us through more comprehensive
coverage and the further adoption of our newest services in pregnancy, parenting
and menopause support.

“More than ever, these results once again affirm the critical importance of
these benefits to employers,” continued Anevski. “We believe the energy and
success we're seeing reflect how Progyny remains uniquely positioned to
consistently deliver meaningful value and cost trend control to employers, which
is particularly impactful given the pressures employers are facing from broader
medical cost inflation.

“As we look into next year, we believe we're well-positioned to extend this
momentum into 2027, as we're exiting the year with our strongest ever set-up in
terms of our number of opportunities and the overall size and quality of the
pipeline, as our demonstrated ability to effectively bend the cost curve
positions us well for continued success.”

“We achieved strong top- and bottom-line growth this quarter, reflecting that
member engagement was consistent with our expectations, and we are pleased to be
in a position to raise the midpoint of our full year guidance,” said Mark
Livingston, Chief Financial Officer of Progyny. “In addition to the strong
results this quarter, we continued to maintain a high conversion of Adjusted
EBITDA to operating cash flow, which has provided us with the flexibility to
continue investing in our platform while also returning value to shareholders
through the repurchase of nearly 11 million shares this year.”
Third Quarter 2026 Highlights:
                                                                                
  (unaudited; in thousands,                                                     
  except per                        3Q 2026                3Q 2025              
  share amounts)                                                                
  Revenue                                      $341,254               $313,346  
  Gross Profit                                  $83,740                $72,835  
  Gross Margin                                    24.5%                  23.2%  
  Net Income                                    $26,252                $13,864  
  Net Income per Diluted Share1                   $0.32                  $0.15  
  Adjusted Earnings per Diluted                   $0.52                  $0.45  
  Share2                                                                        
  Adjusted EBITDA2                              $58,439                $54,968  
  Adjusted EBITDA Margin2                         17.1%                  17.5%  
  Trailing Twelve-Month                                                         
  Operating Cash                               $207,182               $208,153  
  Flow                                                                          
                                                                                
1. Net income per diluted share reflects weighted-average shares outstanding as
adjusted for potential dilutive securities, including options, restricted stock
units, and shares issuable under the employee stock purchase plan .
                                       1                                        
2. Adjusted Earnings per Diluted Share, Adjusted EBITDA, and Adjusted EBITDA
margin are financial measures that are not required by, or presented in
accordance with U.S. generally accepted accounting principles ("GAAP"). Please
see Annex A of this press release for a reconciliation of Adjusted Earnings per
Diluted Share to earnings per share, and Adjusted EBITDA to net income, the most
directly comparable financial measures stated in accordance with GAAP for each
of the periods presented. We calculate Adjusted Earnings per Diluted Share as
net income per diluted share excluding the impact of stock-based compensation,
adjusted for the impact of taxes. We calculate Adjusted EBITDA margin as
Adjusted EBITDA divided by revenue.
                                                                                
  Financial Highlights                                                          
                                                                                
Revenue was $341.3 million, an 8.9% increase as compared to the $313.3 million
reported in the third quarter of 2025, due to an increase in the number of
clients and covered lives.

• Fertility benefit services revenue was $223.4 million, a 10.6% increase from
the $201.9 million reported in the third quarter of 2025.

• Pharmacy benefit services revenue was $117.9 million, a 5.8% increase as
compared to the $111.4 million reported in the third quarter of 2025.

Gross profit was $83.7 million, an increase of 15% from the $72.8 million
reported in the third quarter of 2025, reflecting ongoing efficiencies realized
in the delivery of our care management services as well as a decrease in stock-
based compensation expense . Gross margin was 24.5%, as compared to 23.2%
reported in the prior year .

Net income was $26.3 million, or $0.32 income per diluted share, as compared to
the $13.9 million, or $0.15 income per diluted share, reported in the third
quarter of 2025. The higher net income was due primarily to the higher gross
profit and lower stock-based compensation expense, which was partially offset by
lower interest and other income, net.

Adjusted EBITDA was $58.4 million, an increase of 6.3% as compared to the $55.0
million reported in the third quarter of 2025, as the higher gross profit was
partially offset by planned investments to expand the features and functionality
of our platform . Adjusted EBITDA margin was 17.1% as compared to the 17.5%
Adjusted EBITDA margin in the third quarter of 2025. Refer to Annex A for a
reconciliation of Adjusted EBITDA to net income.
                                                                                
  Cash Flow                                                                     
                                                                                
Net cash provided by operating activities in the third quarter of 2026 was $56.6
million, as compared to $50.7 million in the prior year period. Cash flow
reflects the timing impact of certain working capital items in both periods.
                                                                                
  Balance Sheet and Financial Position                                          
                                                                                
As of September 30, 2026, the Company had total working capital of approximately
$224.4 million and no debt. This included cash and cash equivalents and
marketable securities of $195.6 million, a decrease of $41.3 million from the
balances as of June 30, 2026, as the operating cash flow generated was offset by
share repurchase activity during the quarter. The Company's $200 million
revolving credit facility remains undrawn, and the Company has no planned use
for the facility at this time.
                                                                                
  Share Repurchase Activity                                                     
                                                                                
During the third quarter of 2026, the Company repurchased nearly 3 million
shares of its common stock for a total cost of $82.7 million through its May
2026 share repurchase program, which provided for a total authorization of up to
$200 million. To date, the Company has repurchased nearly 5.5 million shares of
its common stock under this most recent program, and approximately $51 million
remains under the existing authorization. In combination with its predecessor
program which began in November 2025 and concluded earlier this year, the
Company has now repurchased nearly 11 million shares thus far in 2026, and
approximately 14.3 million shares overall since November 2025.
                                                                                
  Key Metrics                                                                   
                                                                                
The Company had 607 fertility and family building clients as of September 30,
2026, as compared to 553 clients as of September 30, 2025.
                                       2                                        
                                                                                
          Three                                Nine                             
          Mont…                              Months                             
          Ended                               Ended                             
          Sept…                              Septe…                             
            30,                                 30,                             
           2026             2025               2026             2025            
  Ass…                                                                          
  Rep…                                                                          
  Tre…             16,7…            15,9…              49,3…            49,079  
  (AR…                                                                          
  Cyc…                                                                          
  Uti…                                                                          
  -                0.56%            0.54%              1.10%             1.06%  
  All                                                                           
  Mem…                                                                          
  Uti…                                                                          
  -                0.49%            0.47%              0.91%             0.88%  
  Fem…                                                                          
  Onl…                                                                          
  Ave…             7,17…            6,75…              7,16…            6,730…  
  Mem…                                                                          
                                                                                
* Represents the number of ART cycles performed, including IVF with a fresh
embryo transfer, IVF freeze all cycles/embryo banking, frozen embryo transfers,
and egg freezing. Includes ART cycles performed in the first half of 2025 under
the extended transition of care agreement with the large client who did not
renew its service agreement.

** Represents the member utilization rate for all fertility and family building
services, including, but not limited to, ART cycles, initial consultations,
IUIs, and genetic testing. The utilization rate for all members includes all
unique members (female and male) who utilize the benefit during that period,
while the utilization rate for female only includes only unique females who
utilize the benefit during that period. For purposes of calculating utilization
rates in any given period, the results reflect the number of unique members
utilizing the benefit for that period. Individual periods cannot be combined as
member treatments may span multiple periods. Utilization for the nine month
period in 2025 excludes activity under the extended transition of care agreement
that ended June 30, 2025 with the large client who did not renew its service
agreement, as only members meeting certain criteria were eligible to use the
benefit.

***Includes approximately 300,000 members from a single client who are not
reflected in utilization as a result of the client's chosen benefit design. 2025
excludes the limited number of members who were eligible to use the benefit
under the extended transition of care agreement that ended June 30, 2025 with
the large client who did not renew its service agreement.
                                                                                
  Financial Outlook                                                             
                                                                                
As the fourth quarter begins, member activity continues to remain healthy. In
light of the strong results over the first nine months of the year, as well as
our expectations for member engagement over the remainder of the year, we're
raising the midpoint of our full year guidance.

The majority of the clients and lives added in the most recent selling season
are expected to go live in the first quarter of 2027, though a meaningful number
of lives are expected to launch mid-year. In addition, a number of the newest
clients have already launched their benefit in 2026. Once all new clients are
live in 2027, the Company anticipates having in excess of 660 clients,
representing approximately 8.3 million covered lives.

As it relates to 2027, consistent with past practice, the Company anticipates
providing financial guidance when it reports its year-end results in February.
The Company is providing the following financial guidance for both the three-
month and full year periods ending December 31, 2026.

• Full Year 2026 Outlook:

o Revenue is projected to be $1.365 billion to $1.385 billion, reflecting growth
of 5.9% to 7.5%; excluding the $48.5 million of revenue in 2025 from the large
client who was under a transition agreement in the first half of 2025, revenue
is expected to increase by 10.1% to 11.7%
o Net income is projected to be $107.0 million to $110.6 million, or $1.30 to
$1.35 per diluted share, on the basis of approximately 82.0 million assumed
weighted-average fully diluted-shares outstanding
o Adjusted EBITDA 1 is projected to be $235.0 million to $240.0 million

o Adjusted earnings per diluted share 1 is projected to be $2.09 to $2.13

• Fourth Quarter of 2026 Outlook:

o Revenue is projected to be $344.7 million to $364.7 million, reflecting growth
of 8.3% to 14.6%
o Net income is projected to be $28.5 million to $32.1 million, or $0.36 to
$0.41 per diluted share, on the basis of approximately 79.0 million assumed
weighted-average fully diluted-shares outstanding
o Adjusted EBITDA 1 is projected to be $57.9 million to $62.9 million

o Adjusted earnings per diluted share 1 is projected to be $0.53 to $0.58

1. Adjusted EBITDA and Adjusted earnings per diluted share are financial
measures that are not required by, or presented in accordance with, GAAP. Please
see Annex A of this press release for a reconciliation of forward-looking
Adjusted EBITDA to forward-looking net
                                       3                                        
income and Adjusted net income to net income, the most directly comparable
financial measures stated in accordance with GAAP, for the period presented.
                                                                                
  Conference Call Information                                                   
                                                                                
Progyny will host a conference call at 4:45 P.M. Eastern Time (1:45 p.m. Pacific
Time) today, November 4, 2026, to discuss its financial results. Interested
participants from the United States may join by calling 1.866.825.7331 and using
conference ID 265484. Participants from international locations may join by
calling 1.973.413.6106 and using the same conference ID. A replay of the call
will be available until November 11, 2026 at 5:00 p.m. Eastern Time by dialing
1.800.332.6854 (U.S. participants) or 1.973.528.0005 (international) and
entering passcode 265484. A live audio webcast of the call and subsequent replay
will also be available through the Events & Presentations section of the
Company’s Investor Relations website at investors.progyny.com.
                                                                                
  About Progyny                                                                 
                                                                                
Progyny (Nasdaq: PGNY) is a global leader in women’s health and family building
solutions, trusted by leading employers, health plans, and benefit purchasers
worldwide. Through its comprehensive and personalized approach, Progyny supports
members across fertility and family building, pregnancy and postpartum,
menopause and midlife, and parent and child well-being journeys. Progyny
combines differentiated clinical care, integrated pharmacy support through
Progyny Rx®, and personalized guidance from Progyny Care Advocates® to deliver
improved member experiences and better health outcomes. For more information,
visit www.progyny.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. We intend such forward-looking
statements to be covered by the safe harbor provisions for forward-looking
statements contained in Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. All
statements contained in this press release other than statements of historical
fact, are forward-looking statements including, without limitation, statements
regarding our financial outlook for the fourth quarter and full year 2026,
including the impact of our sales season and client launches; our anticipated
number of clients and covered lives for 2026; our expected utilization rates and
mix; the demand for our solutions; our expectations for our selling season for
2027 launches; our positioning to successfully manage economic uncertainty on
our business; the timing of client decisions; our ability to retain existing
clients and acquire new clients; and our business strategy, plans, goals and
expectations concerning our market position, future operations, and other
financial and operating information. The words “anticipates,” “assumes,”
“believe,” “contemplate,” “continues, ” “could,” “estimates,” “expects,”
“future,” “intends,” “may,” “plans,” “predict,” “potential,” “project,” “seeks,”
“should,” “target,” “will,” and the negative of these or similar expressions and
phrases are intended to identify forward-looking statements, though not all
forward-looking statements use these words or expressions.

Forward-looking statements are neither promises nor guarantees, but involve
known and unknown risks, uncertainties and other important factors that may
cause our actual results, performance or achievements to be materially different
from any future results, performance or achievements expressed or implied by the
forward-looking statements. These risks include, without limitation, failure to
meet our publicly announced guidance or other expectations about our business;
competition in the market in which we operate; our history of operating losses
and ability to sustain profitability; unfavorable conditions in our industry or
the United States economy; our limited operating history and the difficulty in
predicting our future results of operations; our ability to attract and retain
clients and increase the adoption of services within our client base; the loss
of any of our largest client accounts; changes in the technology industry;
changes or developments in the health insurance market; negative publicity in
the health benefits industry; lags, failures or security breaches in our
computer systems or those of our vendors; a significant change in the
utilization of our solutions; our ability to offer high-quality support;
positive references from our existing clients; our ability to develop and expand
our marketing and sales capabilities; the rate of growth of our future revenue;
the accuracy of the estimates and assumptions we use to determine the size of
target markets; our ability to successfully manage our growth; reductions in
employee benefits spending; seasonal fluctuations in our sales; the adoption of
new solutions and services by our clients or members; our ability to innovate
and develop new offerings; our ability to adapt and respond to the changing
medical landscape,
                                       4                                        
regulations, and client needs, requirements or preferences; our ability to
maintain and enhance our brand; our ability to attract and retain members of our
management team, key employees, or other qualified personnel; risks related to
any litigation against us; our ability to maintain our Center of Excellence
network of healthcare providers; our strategic relationships with and monitoring
of third parties; our ability to maintain our pharmacy distribution network if
there is a disruption to our network or its associated supply chains; our
relationship with key pharmacy program partners or any decline in rebates
provided by them; our ability to maintain our relationships with benefits
consultants; exposure to credit risk from our members; risks related to
government regulation; risks related to our business with government entities;
our ability to protect our intellectual property rights; risks related to
acquisitions, strategic investments, or partnerships; federal tax reform and
changes to our effective tax rate; the imposition of state and local state
taxes; our ability to utilize a portion of our net operating loss or research
tax credit carryforwards; our ability to develop or maintain effective internal
control over financial reporting; and our ability to adapt and respond to the
changing SEC or stakeholder expectations regarding environmental, social and
governance practices. For a detailed discussion of these and other risk factors,
please refer to our filings with the Securities and Exchange Commission (the
“SEC”), including in the section entitled “Risk Factors” in our Annual Report on
Form 10-K for the fiscal year ended December 31, 2025, and subsequent reports
that we file with the SEC, which are available at http://investors.progyny.com
and on the SEC’s website at https://www.sec.gov .

Forward-looking statements represent our management’s beliefs and assumptions
only as of the date of this press release. Our actual future results could
differ materially from what we expect. Except as required by law, we assume no
obligation to update these forward-looking statements publicly, or to update the
reasons.
                                                                                
  Non-GAAP Financial Measures                                                   
                                                                                
In addition to disclosing financial measures prepared in accordance with U.S.
generally accepted accounting principles (“GAAP”), this press release and the
accompanying tables include the non-GAAP financial measures Adjusted EBITDA,
Adjusted EBITDA margin, and Adjusted earnings per diluted share.

Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share
are supplemental financial measures that are not required by, or presented in
accordance with, GAAP. We believe that these non-GAAP measures, when taken
together with our GAAP financial results, provide meaningful supplemental
information regarding our operating performance and facilitates internal
comparisons of our historical operating performance on a more consistent basis
by excluding certain items that may not be indicative of our business, results
of operations or outlook. In particular, we believe that the use of Adjusted
EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share are
helpful to our investors as they are measures used by management in assessing
the health of our business, determining incentive compensation, evaluating our
operating performance, and for internal planning and forecasting purposes.

Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share
are presented for supplemental informational purposes only, have limitations as
analytical tools and should not be considered in isolation or as a substitute
for financial information presented in accordance with GAAP. Some of the
limitations of Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings
per diluted share include: (1) it does not properly reflect capital commitments
to be paid in the future; (2) although depreciation and amortization are non-
cash charges, the underlying assets may need to be replaced and Adjusted EBITDA
does not reflect these capital expenditures; (3) it does not consider the impact
of stock-based compensation expense; (4) it does not reflect other non-operating
income and expenses, including interest and other income, net; and (5) it does
not reflect tax payments that may represent a reduction in cash available to us.
In addition, our non-GAAP measures may not be comparable to similarly titled
measures of other companies because they may not calculate such measures in the
same manner as we calculate these measures, limiting their usefulness as
comparative measures. Because of these limitations, when evaluating our
performance, you should consider Adjusted EBITDA, Adjusted EBITDA margin, and
Adjusted earnings per diluted share alongside other financial performance
measures, including our net income, gross margin, and our other GAAP results.
                                       5                                        
We calculate Adjusted EBITDA as net income, adjusted to exclude depreciation and
amortization; stock-based compensation expense; interest and other income, net;
and provision for income taxes. We calculate Adjusted EBITDA margin as Adjusted
EBITDA divided by revenue. We calculate Adjusted earnings per diluted share as
net income per diluted share excluding the impact of stock-based compensation,
adjusted for the associated impact of taxes. Please see Annex A: “Reconciliation
of GAAP to Non-GAAP Financial Measures” elsewhere in this press release.
For Further Information, Please
Contact:

Investors:

James Hart

[email protected]

Media:

Alexis Ford

[email protected]
                                       6                                        
                                                                                
                                 PROGYNY, INC.                                  
                                                                                
                                                                                
                          Consolidated Balance Sheets                           
                                                                                
                                  (Unaudited)                                   
                                                                                
               (in thousands, except share and per share amounts)               
                                                                                
  ASSETS                     September 30,              December 31,            
  Current assets:            2026                       2025                    
 ────────────────────────────────────────────────────────────────────────────── 
  Cash and cash              $               116,820    $              112,238  
  equivalents                                                                   
  Marketable securities                       78,765                   197,858  
  Accounts receivable,                                                          
  net of $54,156 and                                                            
  $55,659 of allowances                      249,182                   220,287  
  at September 30,                                                              
  2026 and December 31,                                                         
  2025, respectively                                                            
  Prepaid expenses and                                                          
  other current                               19,634                    21,392  
  assets                                                                        
  Total current assets                       464,401                   551,775  
  Property and equipment,                     50,252                    29,927  
  net                                                                           
  Operating lease                             22,872                    24,990  
  right-of-use assets                                                           
  Goodwill                                    19,832                    19,978  
  Intangible assets, net                       5,527                     6,216  
  Deferred tax assets,                        93,083                    93,013  
  net                                                                           
  Other noncurrent assets                     19,826                    16,536  
  Total assets               $               675,793    $              742,435  
  LIABILITIES AND                                                               
  STOCKHOLDERS’ EQUITY                                                          
  Current liabilities:                                                          
  Accounts payable           $               148,001    $              124,071  
  Accrued expenses and                                                          
  other current                               92,038                    78,320  
  liabilities                                                                   
  Total current                              240,039                   202,391  
  liabilities                                                                   
  Operating lease                             21,726                    24,000  
  noncurrent liabilities                                                        
  Total liabilities                          261,765                   226,391  
  Commitments and                                                               
  Contingencies                                                                 
  STOCKHOLDERS' EQUITY                                                          
  Common stock, $0.0001                                                         
  par value;                                                                    
  1,000,000,000 shares                                                          
  authorized; at                                                                
  September 30, 2026 and                                                        
  December 31,                                                                  
  2025, respectively;                              9                         9  
  100,087,996 and                                                               
  99,049,485 shares                                                             
  issued; 74,723,072 and                                                        
  83,365,696 outstanding                                                        
  at September 30,                                                              
  2026 and December 31,                                                         
  2025, respectively                                                            
  Additional paid-in                         753,524                   700,785  
  capital                                                                       
  Treasury stock, at                                                            
  cost, $0.0001 par                                                             
  value; 25,980,904 and                                                         
  16,299,769 shares                         -621,041                  -388,075  
  at September 30, 2026                                                         
  and December 31,                                                              
  2025, respectively                                                            
  Accumulated earnings                       281,363                   202,827  
  Accumulated other                              173                       498  
  comprehensive income                                                          
  Total stockholders’                        414,028                   516,044  
  equity                                                                        
  Total liabilities and                                                         
  stockholders’              $               675,793    $              742,435  
  equity                                                                        
                                                                                
                                       7                                        
                                                                                
                                 PROGYNY, INC.                                  
                                                                                
                                                                                
                     Consolidated Statements of Operations                      
                                                                                
                                  (Unaudited)                                   
                                                                                
               (in thousands, except share and per share amounts)               
                                                                                
                     Three                               Nine                   
                    Months                             Months                   
                     Ended                              Ended                   
                  Septemb…                           Septemb…                   
            2026       30,    2025             2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Reven…    $      341,254    $     313,346    $     1,020,2…    $     970,258  
  Cost                                                                          
  of               257,514          240,511           764,157          742,655  
  servi…                                                                        
  Gross             83,740           72,835           256,112          227,603  
  profit                                                                        
  Opera…                                                                        
  expen…                                                                        
  Sales                                                                         
  and               18,063           17,935            53,021           54,126  
  marke…                                                                        
  Gener…                                                                        
  and               30,495           33,373            92,527          103,422  
  admin…                                                                        
  Total                                                                         
  opera…            48,558           51,308           145,548          157,548  
  expen…                                                                        
  Income                                                                        
  from              35,182           21,527           110,564           70,055  
  opera…                                                                        
  Inter…                                                                        
  and                                                                           
  other              1,234            2,437             3,872            7,523  
  incom…                                                                        
  net                                                                           
  Income                                                                        
  before            36,416           23,964           114,436           77,578  
  income                                                                        
  taxes                                                                         
  Provi…                                                                        
  for               10,164           10,100            35,900           31,543  
  income                                                                        
  taxes                                                                         
  Net       $       26,252    $      13,864    $       78,536    $      46,035  
  income                                                                        
  Net                                                                           
  income                                                                        
  per                                                                           
  share:                                                                        
  Basic     $         0.34    $        0.16    $         1.00    $        0.54  
  Dilut…    $         0.32    $        0.15    $         0.95    $        0.51  
  Weigh…                                                                        
  shares                                                                        
  used                                                                          
  in                                                                            
  compu…                                                                        
  net                                                                           
  income                                                                        
  per                                                                           
  share:                                                                        
  Basic           76,226,…          86,017…          78,400,…          85,780…  
  Dilut…          81,172,…          90,226…          82,726,…          89,884…  
                                                                                
                                       8                                        
                                                                                
                                 PROGYNY, INC.                                  
                                                                                
                                                                                
                     Consolidated Statements of Cash Flows                      
                                                                                
                                  (Unaudited)                                   
                                                                                
                                 (in thousands)                                 
                                                                                
                                 Nine Months Ended                              
                                 September 30,                                  
  OPERATING ACTIVITIES           2026                           2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Net income                     $                    78,536    $       46,035  
  Adjustments to reconcile                                                      
  net income to                                                                 
  net cash provided by                                                          
  operating                                                                     
  activities:                                                                   
  Deferred tax expense                                    29                31  
  Non-cash interest expense                              591               279  
  Depreciation and                                     5,257             3,581  
  amortization                                                                  
  Loss on disposal of                                                           
  property and                                           711                79  
  equipment                                                                     
  Stock-based compensation                            61,305            97,068  
  expense                                                                       
  Bad debt expense                                    13,243            15,345  
  Net accretion of discounts                                                    
  on marketable                                        1,345              -432  
  securities                                                                    
  Changes in operating assets                                                   
  and                                                                           
  liabilities:                                                                  
  Accounts receivable, net                           -42,161           -32,155  
  Prepaid expenses and other                                                    
  current                                              2,811           -14,859  
  assets                                                                        
  Accounts payable                                    23,799            27,660  
  Accrued expenses and other                                                    
  current                                             11,900            13,317  
  liabilities                                                                   
  Other noncurrent assets and                         -4,387                40  
  liabilities                                                                   
  Net cash provided by                                                          
  operating                                          152,979           155,989  
  activities                                                                    
  INVESTING ACTIVITIES                                                          
  Purchase of property and                           -21,931           -12,796  
  equipment, net                                                                
  Purchase of marketable                             -34,162          -311,513  
  securities                                                                    
  Sale of marketable                                 151,222           166,380  
  securities                                                                    
  Acquisition of business,                                                      
  net of cash                                              —            -9,340  
  acquired                                                                      
  Net cash provided by (used                                                    
  in) investing                                       95,129          -167,269  
  activities                                                                    
  FINANCING ACTIVITIES                                                          
  Repurchase of common stock                        -231,406                 —  
  Payment of excise tax from                                                    
  repurchase of                                         -528                 —  
  common stock                                                                  
  Proceeds from exercise of                               38                23  
  stock options                                                                 
  Issuance costs on credit                                 —            -3,087  
  facility                                                                      
  Payment of employee taxes                                                     
  related to                                         -12,563            -8,820  
  equity awards                                                                 
  Proceeds from contributions                                                   
  to employee                                          1,051               781  
  stock purchase plan                                                           
  Net cash used in financing                        -243,408           -11,103  
  activities                                                                    
  Effect of exchange rate                                                       
  changes on cash,                                       -93                49  
  cash equivalents, and                                                         
  restricted cash                                                               
  Net increase (decrease) in                                                    
  cash, cash                                           4,607           -22,334  
  equivalents, and restricted                                                   
  cash                                                                          
  Cash, cash equivalents, and                                                   
  restricted                                         114,193           162,314  
  cash, beginning of period                                                     
  Cash, cash equivalents, and                                                   
  restricted                     $                   118,800    $      139,980  
  cash, end of period                                                           
  Cash and cash equivalents      $                   116,820    $      133,982  
  Restricted cash included                                                      
  within prepaid                                       1,054                 —  
  expenses and other current                                                    
  assets                                                                        
  Restricted cash included                                                      
  within other                                           926             5,998  
  noncurrent assets                                                             
  Total cash, cash                                                              
  equivalents, and               $                   118,800    $      139,980  
  restricted cash                                                               
  SUPPLEMENTAL DISCLOSURE OF                                                    
  CASH FLOW                                                                     
  INFORMATION                                                                   
  Cash paid for income taxes,                                                   
  net of                         $                    32,643    $       39,898  
  refunds received                                                              
  SUPPLEMENTAL DISCLOSURE OF                                                    
  NON-CASH                                                                      
  INVESTING AND FINANCING                                                       
  ACTIVITIES                                                                    
  Additions of property and                                                     
  equipment, net                                                                
  included in accounts           $                     2,399    $          781  
  payable and accrued                                                           
  expenses                                                                      
  Repurchases of common stock                                                   
  recorded in                                                                   
  accrued expenses and other     $                     1,501    $            —  
  current                                                                       
  liabilities                                                                   
  Excise tax payable on                                                         
  common stock                                                                  
  included in accrued            $                     2,061    $            —  
  expenses and other                                                            
  current liabilities                                                           
  Payment of employee taxes                                                     
  related to                                                                    
  equity awards included in      $                       291    $           22  
  accrued                                                                       
  expenses and other current                                                    
  liabilities                                                                   
                                                                                
                                       9                                        
                                                                                
                                    ANNEX A                                     
                                                                                
                                                                                
                                 PROGYNY, INC.                                  
                                                                                
                                                                                
             Reconciliation of GAAP to Non-GAAP Financial Measures              
                                                                                
                                  (Unaudited)                                   
                                                                                
               (in thousands, except share and per share amounts)               
Costs of Services, Gross Margin and Operating Expenses Excluding Stock-Based
Compensation Calculation

The following table provides a reconciliation of cost of services, gross profit,
sales and marketing and general and administrative expenses to each of these
measures excluding the impact of stock-based compensation expense for each of
the periods presented:
                                                                                
       T…                                    …                                  
       M…                                    …                                  
       E…                                    …                                  
       S…                                    …                                  
       3…                                    …                                  
       2…                                    …                                  
 ────────────────────────────────────────────────────────────────────────────── 
                    …                                    S…                     
       G…           …           N…           …           C…           …         
                    …                                    E…                     
  …                                                                             
  …    $      2…    $      …    $      2…    $      …    $      -…    $      …  
  …                                                                             
  …    $      8…    $      …    $      9…    $      …    $      9…    $      …  
  …                                                                             
  …                                                                             
  …    $      1…    $      …    $      1…    $      …    $      -…    $      …  
  …                                                                             
  …                                                                             
  …    $      3…    $      …    $      2…    $      …    $      -…    $      …  
  …                                                                             
  …                                                                             
  …                                                                             
  a                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        …   %       1…  %        …   %       2…  %        …   %       2…  %  
  …                                                                             
  …                                                                             
  …        …   %       -…  %        …   %       5…  %        …   %       3…  %  
  …                                                                             
  …                                                                             
  …        …   %       -…  %        …   %       1…  %        …   %       5…  %  
  …                                                                             
       N…                                    …                                  
       M…                                    …                                  
       E…                                    …                                  
       S…                                    …                                  
       3…                                    …                                  
       2…                                    …                                  
                    …                                    S…                     
       G…           …           N…           …           C…           …         
                    …                                    E…                     
  …                                                                             
  …    $      7…    $      …    $      7…    $      …    $      -…    $      …  
  …                                                                             
  …    $      2…    $      …    $      2…    $      …    $      2…    $      …  
  …                                                                             
  …                                                                             
  …    $      5…    $      …    $      3…    $      …    $      -…    $      …  
  …                                                                             
  …                                                                             
  …    $      9…    $      …    $      6…    $      …    $      -…    $      …  
  …                                                                             
  …                                                                             
  …                                                                             
  a                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …        …   %       1…  %        …   %       2…  %        …   %       2…  %  
  …                                                                             
  …                                                                             
  …        …   %       -…  %        …   %       5…  %        …   %       3…  %  
  …                                                                             
  …                                                                             
  …        …   %       -…  %        …   %       1…  %        …   %       6…  %  
  …                                                                             
                                                                                
Note: percentages shown in the table may not cross foot due to rounding.
                                       10                                       
                                                                                
  Adjusted Earnings Per Diluted Share Calculation                               
                                                                                
The following table provides a reconciliation of net income to Adjusted Earnings
Per Diluted Share for each of the periods presented:
                                                                                
        Thr…                                 Nine                               
        mon…                                 Mon…                               
        end…  Se…                            End…  Se…                          
        2026  30,          20…               2026  30,          20…             
 ────────────────────────────────────────────────────────────────────────────── 
  N…    $     26…          $    13,…         $     78…          $    46,…       
  I…                                                                            
  A…                                                                            
  S…                                                                            
  c…               21,…               32…               61,…               97…  
  e…                                                                            
  I…                                                                            
  t…                                                                            
  e…               -5,…               -5…               -10…               -1…  
  of                                                                            
  n…                                                                            
  a…                                                                            
  A…                                                                            
  N…    $          42,…    $          40…    $          129…    $          12…  
  i…                                                                            
  D…          81…               90,…               82…               89,…       
  S…                                                                            
  A…                                                                            
  E…                                                                            
  P…    $     0.…          $    0.45         $     1.…          $    1.42       
  D…                                                                            
  S…                                                                            
                                                                                
                                                                                
  Adjusted EBITDA Calculation                                                   
                                                                                
The following table provides a reconciliation of net income to Adjusted EBITDA
for each of the periods presented:
                                                                                
        Thr…                                 Nine                               
        mon…                                 Mon…                               
        end…  Se…                            End…  Se…                          
        2026  30,          20…               2026  30,          20…             
 ────────────────────────────────────────────────────────────────────────────── 
  N…    $     26…          $    13,…         $     78…          $    46,…       
  i…                                                                            
  A…                                                                            
  D…                                                                            
  a…          2,…               1,2…               5,…               3,5…       
  a…                                                                            
  S…                                                                            
  c…               21,…               32…               61,…               97…  
  e…                                                                            
  I…                                                                            
  a…                                                                            
  o…               -1,…               -2…               -3,…               -7…  
  i…                                                                            
  n…                                                                            
  P…                                                                            
  f…               10,…               10…               35,…               31…  
  i…                                                                            
  t…                                                                            
  A…    $          58,…    $          54…    $          177…    $          17…  
  E…                                                                            
                                                                                
                                       11                                       
Reconciliation of Non-GAAP Financial Guidance for the Three Months Ending
December 31, 2026 and Year Ending December 31, 2026
                                                                                
         Thr…                                                                   
         Mon…                                    Year                           
         End…                                    End…                           
         Dec…                                    Dec…                           
         31,                                     31,                            
         2026                                    2026                           
 ────────────────────────────────────────────────────────────────────────────── 
         Low                 High                Low             High           
  Re…    $     344…          $     364…          $       1,3…    $       1,38…  
  Net    $     28,…          $           32,…    $       107…    $       110,…  
  In…                                                                           
  Ad…                                                                           
  De…                                                                           
  and                2,7…                2,7…            8,0…            8,000  
  am…                                                                           
  St…                                                                           
  co…                18,…                18,…            79,…            79,5…  
  ex…                                                                           
  In…                                                                           
  and                                                                           
  ot…          -2,…                -2,…                  -6,…            -6,3…  
  in…                                                                           
  net                                                                           
  Pr…                                                                           
  for                10,…                12,…            46,…            48,2…  
  in…                                                                           
  ta…                                                                           
  Ad…    $           57,…    $           62,…    $       235…    $       240,…  
  EB…                                                                           
                                                                                
                                                                                
                     Three                                                      
                    Months                               Year                   
                    Ending                             Ending                   
                  December                           December                   
                  31, 2026                           31, 2026                   
 ────────────────────────────────────────────────────────────────────────────── 
             Low              High              Low              High           
  Net        $      28,464    $       32,064    $     107,000    $     110,600  
  Income*                                                                       
  Add:                                                                          
  Stock-…           18,195            18,195           79,500           79,500  
  compen…                                                                       
  Income                                                                        
  tax                                                                           
  effect            -4,500            -4,500          -15,100          -15,100  
  of                                                                            
  non-GA…                                                                       
  adjust…                                                                       
  Adjust…                                                                       
  Net        $      42,159    $       45,759    $     171,400    $     175,000  
  income*                                                                       
  Diluted         79,000,…          79,000,…         82,000,…          82,000…  
  Shares                                                                        
  Adjust…                                                                       
  Earnin…                                                                       
  Per        $        0.53    $         0.58    $        2.09    $        2.13  
  Diluted                                                                       
  Share                                                                         
                                                                                
* All of the numbers in the tables above reflect our future outlook as of the
date hereof. Net income, Adjusted Net Income and Adjusted EBITDA ranges do not
reflect any estimate for other potential activities and transactions, nor do
they contemplate any discrete income tax items, including the income tax impact
related to equity compensation activity.
                                       12                                       
Assisted Reproductive Technology (ART) Cycles per Unique Female Utilizer

The following tables provide historical trend and guidance assumptions for
average members, female utilization rate, and ART Cycles per Unique Female
Utilizer for the full year and quarterly periods presented:
                                                                                
                                                            G…                  
                                                            A…                  
                                                            F…                  
                                                            Y…                  
                                                            E…                  
                                                            D…                  
                                                            3…                  
                                                            2…                  
 ────────────────────────────────────────────────────────────────────────────── 
      …                                                     L…         H…       
      …                                                     E…         E…       
      …                                                     as         as       
      …                                                     of         of       
                                                            N…         N…       
      …          …          …          …          …         4,         4,       
                                                            2…         2…       
            …          …          …    …          …               …          …  
         …  %       …  %       …  %       …  %    …               …          …  
            …          …          …          …    …               …          …  
            …          …          …          …         …          …          …  
            …          …          …          …         …          …          …  
            …          …          …          …         …          …          …  
                                                                                
1 Calculations for 2024, 2025, and 2026 exclude approximately 300,000 members
from a single client not reflected in female utilizers as a result of the
client's chosen benefit design.

2 Calculations exclude activity from a large client whose program discontinued
for 2025, but who allowed for an extended period of transition of care for
certain members during the first half of 2025.
                                                                                
  Quarterly ART Cycles per Unique Female Utilizer                               
                                                                                
                                                                                
        Th…                                                                     
        Mo…                                                        Year         
        En…                                                        End…         
 ────────────────────────────────────────────────────────────────────────────── 
        Ma…           June           Sep…           Dec…           Dec…         
        31,           30,            30,            31,            31,          
  2…           0.…            0.…            0.…            0.…            0.…  
  2…           0.…            0.…            0.…            0.…            0.…  
  2…           0.…            0.…            0.…            0.…            0.…  
  2…           0.…            0.…            0.…            0.…            0.…  
  2…                                                                            
  L…                                                                            
  E…           0.…            0.…            0.…            0.…            0.…  
  of                                                                            
  G…                                                                            
  R…                                                                            
  2…                                                                            
  H…                                                                            
  E…           0.…            0.…            0.…            0.…            0.…  
  of                                                                            
  G…                                                                            
  R…                                                                            
                                                                                
*Calculations for 2024, 2025, and 2026 exclude approximately 300,000 members
from a single client not reflected in female utilizers as a result of the
client's chosen benefit design.

E indicates the estimated value assumed.
                                       13                                       

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PGNY/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.